目錄:MedChemExpress LLC>>生化試劑>> Vixtimotamab | MCE
供貨周期 | 現(xiàn)貨 | 貨號 | HY-P99958 |
---|---|---|---|
應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)。
CAS No. :
產(chǎn)品活性:Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).
研究領(lǐng)域:Others
作用靶點:Others
In Vitro: Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with EC50s of 1 pM and 2 pM, respectively.
Vixtimotamab (TandAb T564; 4 days) induces T-cell proliferation in PBMCs with an EC50 of 3 pM.
Vixtimotamab (TandAb T564; 25 pM, 48 h) shows cytotoxicity against HL-60 and KG-1a cells.
In Vivo: Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) demonstrates dose-dependent tumor growth delay in a prophylactic HL-60 graft NOD/scid mouse model.
Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) substantially inhibits tumor growth in an established HL-60 xenograft NOD/scid mouse model.
相關(guān)產(chǎn)品:Antitumor agent-67 | Catechin 7-O-β-D-glucopyranoside | Carbobenzoxyproline | ATR-IN-9 | TBTDC | Peucenin 7-O-methyl ether | 6-Hydroxy-4-methylcoumarin | AMT-NHS | Nylidrin hydrochloride | D-(+)-Fucose | OVA Peptide (323-339) | Secretin (swine) | Bletilloside A | Transcriptional Intermediary Factor 2 (TIF2) (740-753) | Pep-1 (uncapped) | Aspochalasin M | Dihydrofuran-3(2H)-one | BPK-29 hydrochloride | pppApG | MEIS-IN-2 | 2′-O-Methyl-8-methyl guanosine | Altertoxin I | Lithospermoside | Acitazanolast | FLAG peptide | [Des-Tyr1]-Met-Enkephalin | α-Carotene | myo-Inositol trispyrophosphate hexa-triethylamine | Myt1-IN-2 | Simetride
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學(xué)
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。